Financhill
Sell
27

TOVX Quote, Financials, Valuation and Earnings

Last price:
$1.19
Seasonality move :
-9.97%
Day range:
$1.07 - $1.20
52-week range:
$1.03 - $17.11
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.59x
P/B ratio:
0.17x
Volume:
38K
Avg. volume:
88K
1-year change:
-88.83%
Market cap:
$3.2M
Revenue:
--
EPS (TTM):
-$26.66

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
TOVX
Theriva Biologics
-- -$5.50 -- -8.25% $6.00
ATNM
Actinium Pharmaceuticals
-- -$0.39 -100% -22.58% $5.00
NBY
NovaBay Pharmaceuticals
$2.5M -$0.24 14.03% -95.43% $0.85
NNVC
Nanoviricides
-- -$0.20 -- -26.67% --
OGEN
Oragenics
-- -- -- -- $1.00
PTN
Palatin Technologies
-- -$0.42 -100% -67.93% $7.00
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
TOVX
Theriva Biologics
$1.15 $6.00 $3.2M -- $0.00 0% 1.59x
ATNM
Actinium Pharmaceuticals
$1.23 $5.00 $38.4M -- $0.00 0% --
NBY
NovaBay Pharmaceuticals
$0.63 $0.85 $3.1M -- $0.00 0% 0.07x
NNVC
Nanoviricides
$1.23 -- $19.2M -- $0.00 0% --
OGEN
Oragenics
$0.28 $1.00 $3.4M -- $0.00 0% 1.10x
PTN
Palatin Technologies
$0.79 $7.00 $20.6M -- $0.00 0% --
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
TOVX
Theriva Biologics
-- -2.868 -- --
ATNM
Actinium Pharmaceuticals
-- -1.121 -- 9.03x
NBY
NovaBay Pharmaceuticals
4.54% 0.646 1.51% 0.75x
NNVC
Nanoviricides
-- 1.325 -- --
OGEN
Oragenics
-- 3.509 -- --
PTN
Palatin Technologies
-- -1.737 -- 0.99x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
TOVX
Theriva Biologics
-- -$4.6M -- -- -- -$4.7M
ATNM
Actinium Pharmaceuticals
-- -$12.6M -95.08% -95.08% -12769.14% -$12M
NBY
NovaBay Pharmaceuticals
$1.6M -$1.1M -334.47% -461.38% -44% -$2.1M
NNVC
Nanoviricides
-- -$2.1M -- -- -- -$2.2M
OGEN
Oragenics
-- -$2.4M -- -- -- -$2M
PTN
Palatin Technologies
-- -$5.1M -- -- -2356.3% -$4.8M

Theriva Biologics vs. Competitors

  • Which has Higher Returns TOVX or ATNM?

    Actinium Pharmaceuticals has a net margin of -- compared to Theriva Biologics's net margin of -11511.11%. Theriva Biologics's return on equity of -- beat Actinium Pharmaceuticals's return on equity of -95.08%.

    Company Gross Margin Earnings Per Share Invested Capital
    TOVX
    Theriva Biologics
    -- -$1.60 --
    ATNM
    Actinium Pharmaceuticals
    -- -$0.37 $36.4M
  • What do Analysts Say About TOVX or ATNM?

    Theriva Biologics has a consensus price target of $6.00, signalling upside risk potential of 419.93%. On the other hand Actinium Pharmaceuticals has an analysts' consensus of $5.00 which suggests that it could grow by 306.5%. Given that Theriva Biologics has higher upside potential than Actinium Pharmaceuticals, analysts believe Theriva Biologics is more attractive than Actinium Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    TOVX
    Theriva Biologics
    0 0 0
    ATNM
    Actinium Pharmaceuticals
    2 1 0
  • Is TOVX or ATNM More Risky?

    Theriva Biologics has a beta of 1.159, which suggesting that the stock is 15.945% more volatile than S&P 500. In comparison Actinium Pharmaceuticals has a beta of 0.105, suggesting its less volatile than the S&P 500 by 89.517%.

  • Which is a Better Dividend Stock TOVX or ATNM?

    Theriva Biologics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Actinium Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Theriva Biologics pays -- of its earnings as a dividend. Actinium Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios TOVX or ATNM?

    Theriva Biologics quarterly revenues are --, which are smaller than Actinium Pharmaceuticals quarterly revenues of $81K. Theriva Biologics's net income of -$4.4M is higher than Actinium Pharmaceuticals's net income of -$11.6M. Notably, Theriva Biologics's price-to-earnings ratio is -- while Actinium Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Theriva Biologics is 1.59x versus -- for Actinium Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TOVX
    Theriva Biologics
    1.59x -- -- -$4.4M
    ATNM
    Actinium Pharmaceuticals
    -- -- $81K -$11.6M
  • Which has Higher Returns TOVX or NBY?

    NovaBay Pharmaceuticals has a net margin of -- compared to Theriva Biologics's net margin of -49.65%. Theriva Biologics's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    TOVX
    Theriva Biologics
    -- -$1.60 --
    NBY
    NovaBay Pharmaceuticals
    65.26% -$0.60 $1.1M
  • What do Analysts Say About TOVX or NBY?

    Theriva Biologics has a consensus price target of $6.00, signalling upside risk potential of 419.93%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 34.9%. Given that Theriva Biologics has higher upside potential than NovaBay Pharmaceuticals, analysts believe Theriva Biologics is more attractive than NovaBay Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    TOVX
    Theriva Biologics
    0 0 0
    NBY
    NovaBay Pharmaceuticals
    1 0 0
  • Is TOVX or NBY More Risky?

    Theriva Biologics has a beta of 1.159, which suggesting that the stock is 15.945% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.726, suggesting its less volatile than the S&P 500 by 27.362%.

  • Which is a Better Dividend Stock TOVX or NBY?

    Theriva Biologics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Theriva Biologics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios TOVX or NBY?

    Theriva Biologics quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Theriva Biologics's net income of -$4.4M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Theriva Biologics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Theriva Biologics is 1.59x versus 0.07x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TOVX
    Theriva Biologics
    1.59x -- -- -$4.4M
    NBY
    NovaBay Pharmaceuticals
    0.07x -- $2.4M -$1.2M
  • Which has Higher Returns TOVX or NNVC?

    Nanoviricides has a net margin of -- compared to Theriva Biologics's net margin of --. Theriva Biologics's return on equity of -- beat Nanoviricides's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    TOVX
    Theriva Biologics
    -- -$1.60 --
    NNVC
    Nanoviricides
    -- -$0.14 --
  • What do Analysts Say About TOVX or NNVC?

    Theriva Biologics has a consensus price target of $6.00, signalling upside risk potential of 419.93%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 428.46%. Given that Nanoviricides has higher upside potential than Theriva Biologics, analysts believe Nanoviricides is more attractive than Theriva Biologics.

    Company Buy Ratings Hold Ratings Sell Ratings
    TOVX
    Theriva Biologics
    0 0 0
    NNVC
    Nanoviricides
    0 0 0
  • Is TOVX or NNVC More Risky?

    Theriva Biologics has a beta of 1.159, which suggesting that the stock is 15.945% more volatile than S&P 500. In comparison Nanoviricides has a beta of 1.142, suggesting its more volatile than the S&P 500 by 14.225%.

  • Which is a Better Dividend Stock TOVX or NNVC?

    Theriva Biologics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Theriva Biologics pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios TOVX or NNVC?

    Theriva Biologics quarterly revenues are --, which are smaller than Nanoviricides quarterly revenues of --. Theriva Biologics's net income of -$4.4M is lower than Nanoviricides's net income of -$2M. Notably, Theriva Biologics's price-to-earnings ratio is -- while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Theriva Biologics is 1.59x versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TOVX
    Theriva Biologics
    1.59x -- -- -$4.4M
    NNVC
    Nanoviricides
    -- -- -- -$2M
  • Which has Higher Returns TOVX or OGEN?

    Oragenics has a net margin of -- compared to Theriva Biologics's net margin of --. Theriva Biologics's return on equity of -- beat Oragenics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    TOVX
    Theriva Biologics
    -- -$1.60 --
    OGEN
    Oragenics
    -- -$0.38 --
  • What do Analysts Say About TOVX or OGEN?

    Theriva Biologics has a consensus price target of $6.00, signalling upside risk potential of 419.93%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 257.14%. Given that Theriva Biologics has higher upside potential than Oragenics, analysts believe Theriva Biologics is more attractive than Oragenics.

    Company Buy Ratings Hold Ratings Sell Ratings
    TOVX
    Theriva Biologics
    0 0 0
    OGEN
    Oragenics
    0 1 0
  • Is TOVX or OGEN More Risky?

    Theriva Biologics has a beta of 1.159, which suggesting that the stock is 15.945% more volatile than S&P 500. In comparison Oragenics has a beta of 0.847, suggesting its less volatile than the S&P 500 by 15.305%.

  • Which is a Better Dividend Stock TOVX or OGEN?

    Theriva Biologics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Theriva Biologics pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios TOVX or OGEN?

    Theriva Biologics quarterly revenues are --, which are smaller than Oragenics quarterly revenues of --. Theriva Biologics's net income of -$4.4M is lower than Oragenics's net income of -$2.5M. Notably, Theriva Biologics's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Theriva Biologics is 1.59x versus 1.10x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TOVX
    Theriva Biologics
    1.59x -- -- -$4.4M
    OGEN
    Oragenics
    1.10x -- -- -$2.5M
  • Which has Higher Returns TOVX or PTN?

    Palatin Technologies has a net margin of -- compared to Theriva Biologics's net margin of -2357.27%. Theriva Biologics's return on equity of -- beat Palatin Technologies's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    TOVX
    Theriva Biologics
    -- -$1.60 --
    PTN
    Palatin Technologies
    -- -$0.12 -$111.5K
  • What do Analysts Say About TOVX or PTN?

    Theriva Biologics has a consensus price target of $6.00, signalling upside risk potential of 419.93%. On the other hand Palatin Technologies has an analysts' consensus of $7.00 which suggests that it could grow by 785.18%. Given that Palatin Technologies has higher upside potential than Theriva Biologics, analysts believe Palatin Technologies is more attractive than Theriva Biologics.

    Company Buy Ratings Hold Ratings Sell Ratings
    TOVX
    Theriva Biologics
    0 0 0
    PTN
    Palatin Technologies
    0 0 0
  • Is TOVX or PTN More Risky?

    Theriva Biologics has a beta of 1.159, which suggesting that the stock is 15.945% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.793, suggesting its less volatile than the S&P 500 by 20.66%.

  • Which is a Better Dividend Stock TOVX or PTN?

    Theriva Biologics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Theriva Biologics pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios TOVX or PTN?

    Theriva Biologics quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of $350K. Theriva Biologics's net income of -$4.4M is lower than Palatin Technologies's net income of -$2.4M. Notably, Theriva Biologics's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Theriva Biologics is 1.59x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TOVX
    Theriva Biologics
    1.59x -- -- -$4.4M
    PTN
    Palatin Technologies
    -- -- $350K -$2.4M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is the Market Going to Go Lower?
Is the Market Going to Go Lower?

The last month has been extremely difficult for the stock…

2 Dividend Stocks to Buy in a Recession
2 Dividend Stocks to Buy in a Recession

While many economists and investors initially expected 2025 to be…

Is Ford Stock Undervalued Amid the EV Transition?
Is Ford Stock Undervalued Amid the EV Transition?

There is a lot going on in the electric vehicle…

Stock Ideas

Buy
52
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
56
Is NVDA Stock a Buy?

Market Cap: $3T
P/E Ratio: 41x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Alerts

Sell
49
SMTC alert for Mar 17

Semtech [SMTC] is down 0.49% over the past day.

Buy
62
PLPC alert for Mar 17

Preformed Line Products [PLPC] is up 3.8% over the past day.

Sell
50
NUTX alert for Mar 17

Nutex Health [NUTX] is up 4.82% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock